Literature DB >> 27175250

Modern therapy of young and adult Ph-ALL.

R Bassan1, T Intermesoli2, O Spinelli2, E Oldani2, A Rambaldi2.   

Abstract

Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years.

Entities:  

Keywords:  acute lymphoblastic leukemia; risk classification; treatment strategy

Year:  2012        PMID： 27175250      PMCID： PMC4851211          DOI： 10.1038/leusup.2012.6

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


  9 in total

1.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

Authors:  Monika Brüggemann; Thorsten Raff; Thomas Flohr; Nicola Gökbuget; Makoto Nakao; Jo Droese; Silke Lüschen; Christiane Pott; Matthias Ritgen; Urban Scheuring; Heinz-August Horst; Eckhard Thiel; Dieter Hoelzer; Claus R Bartram; Michael Kneba
Journal:  Blood       Date:  2005-09-29       Impact factor: 22.113

2.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Authors:  Renato Bassan; Orietta Spinelli; Elena Oldani; Tamara Intermesoli; Manuela Tosi; Barbara Peruta; Giuseppe Rossi; Erika Borlenghi; Enrico M Pogliani; Elisabetta Terruzzi; Pietro Fabris; Vincenzo Cassibba; Giorgio Lambertenghi-Deliliers; Agostino Cortelezzi; Alberto Bosi; Giacomo Gianfaldoni; Fabio Ciceri; Massimo Bernardi; Andrea Gallamini; Daniele Mattei; Eros Di Bona; Claudio Romani; Anna Maria Scattolin; Tiziano Barbui; Alessandro Rambaldi
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 3.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

Review 4.  Modern therapy of acute lymphoblastic leukemia.

Authors:  Renato Bassan; Dieter Hoelzer
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

5.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

6.  CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.

Authors:  Francesco Mannelli; Giacomo Gianfaldoni; Tamara Intermesoli; Chiara Cattaneo; Erika Borlenghi; Sergio Cortelazzo; Irene Cavattoni; Enrico Maria Pogliani; Monica Fumagalli; Emanuele Angelucci; Claudio Romani; Fabio Ciceri; Consuelo Corti; Anna Scattolin; Agostino Cortelezzi; Daniele Mattei; Ernesta Audisio; Orietta Spinelli; Elena Oldani; Alberto Bosi; Alessandro Rambaldi; Renato Bassan
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

7.  High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.

Authors:  Nicola Gökbuget; Nadezda Basara; Herrad Baurmann; Joachim Beck; Monika Brüggemann; Helmut Diedrich; Björn Güldenzoph; Gernot Hartung; Heinz-August Horst; Andreas Hüttmann; Guido Kobbe; Ralph Naumann; Richard Ratei; Albrecht Reichle; Hubert Serve; Matthias Stelljes; Andreas Viardot; Mohammed Wattad; Dieter Hoelzer
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

8.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

Authors:  Françoise Huguet; Thibaut Leguay; Emmanuel Raffoux; Xavier Thomas; Kheira Beldjord; Eric Delabesse; Patrice Chevallier; Agnes Buzyn; André Delannoy; Yves Chalandon; Jean-Paul Vernant; Marina Lafage-Pochitaloff; Agnès Chassevent; Véronique Lhéritier; Elizabeth Macintyre; Marie-Christine Béné; Norbert Ifrah; Hervé Dombret
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

9.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Authors:  Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.